(MENAFN- GlobeNewsWire - Nasdaq) Dublin, June 20, 2023 (GLOBE NEWSWIRE) -- The "regulatory report: labelling requirements for medical cannabis products - eu and uk" report has been added to ResearchAndMarkets.com's offering.

This report seeks to outline the labeling and packaging requirements that cannabis-containing medicinal products need to comply with when their placing on the European market is authorized.

The European regulatory framework for medicinal products covers authorized cannabis-containing pharmaceutical products. The latter are subject to the general requirements applicable to medicinal products, meaning that the European Union does not have a specific framework for cannabis-derived medicinal products.

This regulatory report will provide you with:

• A clear and detailed understanding of current regulatory requirements affecting this sector in a specific jurisdiction, enables you to be confident your business and your products are compliant.
• The ability to plan ahead for specific regulatory changes.
• Strategic understanding of the jurisdiction's policy climate enables you to forecast how it might affect business development.
• Sources of further information, for example, links to full texts of legislation and contact details for relevant government offices.

Key Topics Covered:

• Executive summary
• Introduction
• Overview of the authorisation procedure
• Common labelling requirements
• Outer packaging
• Immediate packaging
• Package leaflet
• Labelling requirements for medicinal products in the UK
• Labelling guidelines for marketing authorization holders

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Tags analgesics cannabis

MENAFN20062023004107003653ID1106462994